ReviewLancet (London, England)2017
Ulcerative colitis.
Review in Lancet (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 1,807 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing the Prevalence of Respiratory Impairment in Chronic Inflammatory Bowel Diseases
Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals
Study of the Impact of a Physical Activity Programme on the Quality of Life of Patients With Inflammatory Bowel Disease
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
CMTS0929 for Inflammatory Bowel Disease: a Prospective, Open-label, Single-arm Clinical Study
Multiple Digital Biomarkers for Optimization of IBD Care
Pilot Feasibility and Impact Study of a Remote Adapted Physical Activity Program on the Quality of Life of Patients With Inflammatory Bowel Disease (IBD)
Who cites it
1,807 citing papers in PubMed, 4 syntheses or guidelines pooled it, 3,329 citations in OpenAlex.
- Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- The predictive value of intestinal ultrasound for treatment response in inflammatory bowel disease: a systematic review and pooled data analysis.Journal of Crohn's & colitis · 2026Pooled it
- Neutrophil extracellular traps as a potential therapeutic target in inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data.Journal of Crohn's & colitis · 2026Trial
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies.Journal of gastroenterology and hepatology · 2026Trial
- Sialidase inhibitor modulates gut microbiota and enhances mucosal protection in the treatment of ulcerative colitis.mSystems · 2026Trial
- Safety, Pharmacokinetics, Food effect, and Pharmacodynamics of AJM347, a Selective α4β7 Integrin Antagonist: A First-in-Human Single- and Multiple-Ascending Dose Study in Healthy Male Volunteers.Journal of clinical pharmacology · 2026Trial
- First-In-Human Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of Tilpisertib Fosmecarbil (GS-5290), an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor in Healthy Participants.Journal of clinical pharmacology · 2026Trial
- Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.Advances in therapy · 2026Trial
- Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.United European gastroenterology journal · 2026Trial
- Effect of linaclotide combined with polyethylene glycol on bowel preparation before colonoscopy in patients with constipation.Frontiers in medicine · 2026Trial
- ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment.Drug delivery · 2026Article
- A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.Gut microbes · 2026Article
- Article
- Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.International journal of pharmaceutics: X · 2026Article
- A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease.Inflammopharmacology · 2026Review
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations.Inflammatory bowel diseases · 2026Observational
- Association Between Toothbrushing Habits and Mucosal Healing in Japanese Patients with Ulcerative Colitis.Digestive diseases and sciences · 2026Article
1,747 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of management is to induce and then maintain remission, defined as resolution of symptoms and endoscopic healing. Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs with new targets will rapidly increase in coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.